LLY

1,066.92

+2.16%↑

JNJ

234.6

+1.69%↑

ABBV

217.33

+1.21%↑

UNH

387.88

+1.23%↑

AZN

188.38

-0.66%↓

LLY

1,066.92

+2.16%↑

JNJ

234.6

+1.69%↑

ABBV

217.33

+1.21%↑

UNH

387.88

+1.23%↑

AZN

188.38

-0.66%↓

LLY

1,066.92

+2.16%↑

JNJ

234.6

+1.69%↑

ABBV

217.33

+1.21%↑

UNH

387.88

+1.23%↑

AZN

188.38

-0.66%↓

LLY

1,066.92

+2.16%↑

JNJ

234.6

+1.69%↑

ABBV

217.33

+1.21%↑

UNH

387.88

+1.23%↑

AZN

188.38

-0.66%↓

LLY

1,066.92

+2.16%↑

JNJ

234.6

+1.69%↑

ABBV

217.33

+1.21%↑

UNH

387.88

+1.23%↑

AZN

188.38

-0.66%↓

Kodu・Aktsiate loetelu・Xencor Inc

Xencor Inc

Avatud

SektorTervishoid

11.27 -0.62

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

11.09

Max

11.59

Põhinäitajad
By Trading Economics
Sissetulek	-214M -129M
Müük	-24M 4.5M
Aktsiakasum	-1.71
Kasumimarginaal	-2,854.65
Töötajad	260
EBITDA	-81M -75M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+129.68% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	4. aug 2026

Turustatistika
By TradingEconomics
Turukapital	-170M 820M
Eelmine avamishind	11.89
Eelmine sulgemishind	11.27

Uudiste sentiment

By Acuity

34%

66%

81 / 345 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

7.87 / 10.84 Toetus ja vastupanu

Xencor Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

21. mai 2026, 22:48 UTC

Omandamised, ülevõtmised, äriostud

Conduent to Sell Public Transit Business to Modaxo for $164 Million

21. mai 2026, 16:49 UTC

Tulu

Walmart's Fuel Business Benefits from Rising U.S. Gas Prices, Though Volume Per Transaction Falls -- OPIS

21. mai 2026, 16:26 UTC

Suurimad hinnamuutused turgudel

Spotify Technology Shares Up Amid New AI Tool For Remixing Songs

21. mai 2026, 23:51 UTC

Market Talk

Nikkei Might Rise on Continued Hopes for Possible U.S.-Iran Deal -- Market Talk

21. mai 2026, 23:37 UTC

Tulu

Lenovo Group 4Q Oper Profit $886.0M Vs. $331.0M >0992.HK

21. mai 2026, 23:37 UTC

Tulu

Lenovo Group 4Q Rev $21.60B Vs. $16.98B >0992.HK

21. mai 2026, 23:37 UTC

Tulu

Lenovo Group 4Q Net $521.0M Vs. Net $90.0M >0992.HK

21. mai 2026, 23:34 UTC

Market Talk

Gold Edges Lower Amid Mixed Sentiment -- Market Talk

21. mai 2026, 23:30 UTC

Market Talk

Global Equities Roundup: Market Talk

21. mai 2026, 23:30 UTC

Market Talk

Napier Port Loses Bull Despite Robust 1H Result -- Market Talk

21. mai 2026, 22:33 UTC

Omandamised, ülevõtmised, äriostud

Conduent to Sell Public Transit Business to Modaxo for $164M

21. mai 2026, 21:53 UTC

Tulu

Marvell Stock Notches Its 15th Record Closing High This Year -- Barrons.com

21. mai 2026, 21:02 UTC

Tulu

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, Nebius, Bloom Energy, Applied Digital, Intuit, D-Wave, Spotify, and More -- Barrons.com

21. mai 2026, 20:55 UTC

Tulu

Walmart Sales Rise as It Navigates Higher Fuel Prices -- 2nd Update

21. mai 2026, 20:30 UTC

Kuumad aktsiad

Stocks to Watch Recap: Nvidia, Spotify, Stellantis, Intuit -- WSJ

21. mai 2026, 20:20 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

21. mai 2026, 20:20 UTC

Market Talk

Mexico's Revised 1Q GDP Seen Confirming Contraction -- Market Talk

21. mai 2026, 20:20 UTC

Tulu

Webull 1Q Adj EPS 3c >BULL

21. mai 2026, 20:20 UTC

Tulu

Webull 1Q Rev $159.9M >BULL

21. mai 2026, 20:18 UTC

Market Talk

Mexico's Inflation Seen Easing in Early May -- Market Talk

21. mai 2026, 20:18 UTC

Tulu

Webull 1Q Loss/Shr 4c

21. mai 2026, 19:43 UTC

Market Talk

Oil Futures Lose Ground on Hopes for U.S.-Iran Deal -- Market Talk

21. mai 2026, 19:33 UTC

Market Talk

U.S. Natural Gas Futures Edge Up in Steady Trading -- Market Talk

21. mai 2026, 18:58 UTC

Tulu

Nvidia Is Now the Megacap Cash Machine, and Big Tech Is Footing the Bill -- Barrons.com

21. mai 2026, 18:15 UTC

Market Talk

Gold Higher For Second Consecutive Day -- Market Talk

21. mai 2026, 17:40 UTC

Market Talk

Prolonged War Putting Energy Normalcy Further Away -- Market Talk

21. mai 2026, 17:04 UTC

Market Talk

SpaceX Revealed as Top 10 Bitcoin Holder -- Market Talk

21. mai 2026, 17:01 UTC

Tulu

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, GlobalFoundries, Nebius, Applied Digital, Intuit, Spotify, and More -- Barrons.com

21. mai 2026, 16:20 UTC

Market Talk

Tulu

Stellantis Targets Distant but Constructive -- Market Talk

21. mai 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Xencor Inc Prognoos

Hinnasiht

By TipRanks

129.68% tõus

12 kuu keskmine prognoos

Keskmine 26 USD 129.68%

Kõrge 43 USD

Madal 13 USD

Põhineb 12 Wall Streeti analüütiku instrumendi Xencor Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

12 ratings

Osta

Hoia

Müü

Põhineb 12 analüütiku instrumendi Xencor Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

7.87 / 10.84Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

81 / 345 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Xencor Inc

Xencor, Inc. is a clinical-stage biopharmaceutical company that is focused on discovering and developing engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The Company uses its engineering capabilities to enable its understanding of protein structure and interactions to design XmAb technologies and develop candidates with properties. Its antibody design is focused on the segment of antibodies that interact with target antigens. It is focused on the Fc domain, which is the part of an antibody that interacts with various segments of the immune system and controls antibody structure. The Fc domain is constant and interchangeable among antibodies, and its engineered Fc domains are the XmAb technology, which can be readily substituted for natural Fc domains. Its drug candidates include Plamotamab, XmAb717, Vibecotamab, Tidutamab, XmAb841, XmAb104, XmAb306, XmAb104, XmAb564 and XmAb698.